Ryanodine Receptor Type1 (RYR1) Gene Mutation Analysis
The RYR1 gene is located at 19q13.2 and codes for ryanodine receptor type 1 (RYR1). RYR1 is present across the sarcoplasmic reticulum membrane in muscles. The protein serves as a channel for the controlled release of calcium into the myoplasm. In the resting state, the channel is closed and calcium ions are trapped in the sarcoplasmic reticulum. Under excitatory signals, for example, entry of acetylcholine, the channel opens, releasing calcium ions into the myoplasm initiating muscle contraction. It is also referred to as the excitation-coupling process.
Mutations in RYR1 may result in the formation of malfunctioning protein that fails to close causing leakage and loss of calcium ions from the sarcoplasmic reticulum. Upon excitation there is decreased release of calcium, reduced muscle contraction and muscle weakness. Further, the leaked calcium ions accumulate in the myoplasm enhancing free radical formation resulting in muscle fiber breakdown (rhabdomyolysis).
Volatile anesthetics like halothane, isoflurane, sevoflurane, enflurane, and depolarizing muscle relaxants, especially succinylcholine cause an exaggerated response in people with RYR1 mutations Upon administration of such agents there is a rapid release of calcium into the myoplasm causing muscle rigidity, hyperthermia, tachycardia, and acidosis which may be life threatening. According to the European Malignant Hyperthermia Group (EMHG), 48 variants leading to malignant hyperthermia susceptibility (MHS) have been identified. The FDA has contraindicated the use of these drugs in patients who test positive for these variants. While RYR1 variants are the major cause of MHS, mutations in CACNA1S may also predispose patients to MHS. Pharmacogenetic screening of these genes in patients with a personal or family history of adverse reactions to anesthesia, stress induced fever, muscle cramping or rigidity is beneficial in avoiding anesthesia-related complications.
- As an aid in the diagnosis of malignant hyperthermia susceptibility (MHS)
- Pharmacogenetics for anesthesia and muscle relaxants medication
- Useful in avoiding anesthesia-related complications
Individuals who do not test positive for a designated variant should be considered to have unknown susceptibility to malignant hyperthermia. The use of potent volatile anesthetics and/or succinylcholine should be guided by clinical findings, family history and other genetic and non-genetic factors.
Individuals who do test positive for a designated variant are considered malignant hyperthermia susceptible and are at an increased risk of an MH reaction when administered a potent volatile anesthetic and/or succinylcholine. These agents are contraindicated in these individuals.
A positive result indicates the presence of mutation or pathogenic variants in the RYR1 gene and thus susceptible to malignant hyperthermia.
The FDA has contraindicated the use of volatile anesthesia in patients who test positive. Instead, a non-triggering anesthetic such as nerve block, epidural, spinal, or total intravenous general anesthetic can be administered.
A negative result indicates the absence of mutation or pathogenic variants in the RYR1 gene. However, there are other genes whose variants may result in MHS and a negative result in RYR1 alone cannot rule out the susceptibility.
Negative for mutations analysis (no mutations or pathogenic variants detected)
Whole blood, Lavender-top (EDTA) tube, buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days (preferred)
- Frozen: 30 days
- J Neurol. 2018; 11:2506-2524 [PMID: 30155738]
- Neurotherapeutics. 2018; 10:885-899 [PMID: 30406384]
- Hum Mutat. 2006; 10:977-89 [PMID: 16917943]
- Paediatr Anaesth. 2013; 9:834-41 [PMID: 23617272]
- Anesthesiology. 2020; 12:133(6):1277-1282 [PMID: 32898259]